I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Imaging Very Late Antigen‑4 on MOLT4 Leukemia Tumors with C..:
Mina Kim
;
Kyung-Ho Jung
;
Jung Lim Kim
...
doi:10.1021/acs.molpharmaceut.3c01024.s001. , 2024
Link:
https://doi.org/10.1021/acs.molpharmaceut.3c01024.s001
RT Journal T1
Imaging Very Late Antigen‑4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific 89 Zr-Labeled Natalizumab Immuno-Positron Emission Tomography
UL https://suche.suub.uni-bremen.de/peid=base-ftunivoxfordfig:oai:figshare.com:article_25101252&Exemplar=1&LAN=DE A1 Mina Kim A1 Kyung-Ho Jung A1 Jung Lim Kim A1 Hyun-Jung Koo A1 Hye Jin Jung A1 Hyunjong Lee A1 Kyung-Han Lee YR 2024 K1 Biochemistry K1 Medicine K1 Cell Biology K1 Pharmacology K1 Biotechnology K1 Immunology K1 Cancer K1 Hematology K1 Plant Biology K1 Space Science K1 Chemical Sciences not elsewhere classified K1 α4 integrin level K1 target delivery properties K1 proteasome inhibitor bortezomib K1 positron emission tomography K1 humanized monoclonal antibody K1 7 days postinjection K1 expressing molt4 human K1 93 ± 0 K1 51 ± 0 K1 33 ± 0 K1 22 ± 0 K1 12 ± 0 K1 cultured molt4 cells K1 biodistribution studies confirmed K1 89 </ sup K1 molt4 leukemia tumors K1 g ) K1 followed K1 tumor vla4 regulation K1 contrast tumor uptake K1 ab ) K1 natalizumab K1 labeled natalizumab immuno K1 molt4 tumors K1 labeled natalizumab K1 tumor vla4 K1 tumor uptake K1 resistant leukemia K1 resistant cells K1 natalizumab ' K1 rational application K1 radiolabeled abs K1 providing information K1 noninvasive monitoring K1 multiple myeloma K1 may assist K1 markedly blocked K1 late antigen JF doi:10.1021/acs.molpharmaceut.3c01024.s001 LK http://dx.doi.org/https://doi.org/10.1021/acs.molpharmaceut.3c01024.s001 DO https://doi.org/10.1021/acs.molpharmaceut.3c01024.s001 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)